HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Risk and Benefit of New Therapies

Individualization of care with careful medication selection is increasingly recognized as one of the foundations of care for diabetes, which is not a disease of "one size fits all." The amount of time spent in a condition of hyperglycemia has long been known to raise the risk of complications. Hyperglycemia can leave a negative "metabolic memory" on cells of the vasculature and target organs, encouraging the development of difficulties in the future. Despite the necessity of meeting proper glycemic targets, there is still a gap between the goals specified and the goals achieved. Failure to commence or intensify treatment in a timely manner in persons whose health is expected to improve with this intensification is referred to as clinical inertia

Committee Members
Speaker at Diabetes and Endocrinology 2025 - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Diabetes and Endocrinology 2025 - F Buck Willis

F Buck Willis

Belize Bible College, Belize
Speaker at Diabetes and Endocrinology 2025 - Gretchen Holmes

Gretchen Holmes

Memorial Hospital at Gulfport, United States
Diabetes 2025 Speakers
Speaker at Diabetes and Endocrinology 2025 - Sujith Rajan

Sujith Rajan

NYU Long Island School of Medicine, United States
Speaker at Diabetes and Endocrinology 2025 - Amy Gutman

Amy Gutman

AdventHealth; Tough Love MD, United States
Speaker at Diabetes and Endocrinology 2025 - Paraskevi Theofilou

Paraskevi Theofilou

Hellenic Open University, Greece
Speaker at Diabetes and Endocrinology 2025 - Teji S Dhami

Teji S Dhami

Boost your Health and Wellness, United States

Submit your abstract Today

Watsapp